Enchem (A348370) Q4 2024 earnings summary

Executive summary

• Audit opinion is unqualified; financial statements fairly present financial position and results for 2023 and 2024 under K-IFRS.

• Internal control system is effective as of December 31, 2024.

• Key audit matter: impairment testing of investments in subsidiaries with ongoing losses, requiring significant management judgment and external expert input.

Financial highlights

• Revenue for 2024: ₩40,833 million, down from ₩89,827 million in 2023 (year-over-year decline).

• Operating loss for 2024: ₩77,007 million, compared to a loss of ₩69,140 million in 2023.

• Net loss for 2024: ₩563,088 million, significantly higher than 2023's net loss of ₩35,117 million.

• Basic and diluted EPS for 2024: (₩28,696), compared to (₩2,180) in 2023.

• Total assets at 2024 year-end: ₩913,011 million; total equity: ₩457,875 million.

Outlook and guidance

• No explicit forward-looking guidance provided; management continues to monitor impairment risks and market volatility.